OMERS ADMINISTRATION Corp Buys Shares of 34,800 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

OMERS ADMINISTRATION Corp bought a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 34,800 shares of the company's stock, valued at approximately $342,000. OMERS ADMINISTRATION Corp owned approximately 0.06% of Ginkgo Bioworks as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. SBI Securities Co. Ltd. bought a new position in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $29,000. KBC Group NV purchased a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $31,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $46,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $116,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $144,000. Institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Stock Up 1.8%

NYSE:DNA opened at $8.07 on Tuesday. The company's 50 day moving average price is $7.20 and its 200-day moving average price is $9.08. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $33.20. The stock has a market cap of $472.35 million, a price-to-earnings ratio of -0.62 and a beta of 1.29.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The firm had revenue of $48.32 million for the quarter, compared to analysts' expectations of $38.70 million. As a group, sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.